Report Overview

The UK AADC-Deficiency Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The AADC deficiency is an ultra-rare autosomal recessive disease caused by a non-functional AADC enzyme, which normally synthesizes serotonin and dopamine, among other important compounds. As a result, patients with AADC deficiency lack crucial neurotransmitters, including serotonin, dopamine, norepinephrine, epinephrine, and melatonin, and have severe developmental and motor deficiencies. Symptom onset typically occurs during the first months of life.

The majority of patients present a severe phenotype with early-onset hypotonia, oculogyric crises, ptosis, dystonia, hypokinesia, impaired development, and autonomic dysfunction, a few patients with a milder disease course are known. Patients with AADC deficiency also present with autonomic dysfunction that is characterized by impairment of the sympathetic regulation of heart rate and blood pressure, paroxysmal sweating, emotional instability, and sleep disturbance. This leads to a complex syndrome characterized by motor, behavioral and autonomic symptoms.

The life expectancy of patients with severe AADC deficiency has been reported to be less than a decade. In patients identified with AADC deficiency where gender is reported, the distribution is estimated as; approximately 57% are male and 43% are female. There are around 120 confirmed diagnoses of AADC deficiency worldwide documented in the literature. As per the cases documented in the literature, the average age of symptom onset for AADC deficiency is 2.7 months. Despite the early onset of symptoms, the average age of diagnosis is 3.5 years. The predicted birth rate of individuals with AADC deficiency is estimated to be approximately 1:118,000 in the EU, and these birth rates translate into a current estimate of about 853 living patients with AADC deficiency in the EU.



Market Growth Drivers

The introduction of novel therapies, robust product pipeline, rising government initiatives for creating awareness regarding the AADC-deficiency diagnosis and its treatment, and its available therapeutic options are expected to significantly fuel the market growth over the forecast period.

Additionally, changes in government policies, demand and supply of the market, government intervention programs, and major market share are also playing an essential role to boost the market growth over the forecast period. Moreover, the rise in the number of patients suffering from AADC deficiency is likely to fuel the market growth during the forecast period.

In addition, rise in healthcare expenses and government initiatives for the betterment of health. Increased R&D activities to counter AADC deficiency in children are more likely to propel the market demand during the forecast period.

Market Restraints

Increasing collaboration and technological advancements are projected to bring new growth avenues for market players during the forecast period. While the high cost of approved therapeutics and lower treatment rates hampers the market.